Therapeutic effects of low-dose Bismuth subcitrate on symptoms and health-related quality of life in adult patients with irritable bowel syndrome: A clinica ltrial

Therapeutic effects of low-dose Bismuth subcitrate on symptoms and health-related quality of life in adult patients with irritable bowel syndrome: A clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017081435691N1

Enrollment

120

Registered

2017-09-07

Start date

2015-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Irritable bowel syndrome. Condition 2: Irritable bowel syndrome with diarrhea. Condition 3: Irritable bowel syndrome without diarrhea. irritable colon Irritable bowel syndrome with diarrhea Irritable bowel syndrome without diarrhea

Interventions

Intervention 1: The pharmacotherapy regimen for the intervention group was mebeverine hydrochloride 200 mg capsule once daily ( before breakfast ) and bismuth subcitrate 120 mg tablet twice daily (30

Treatment - Drugs

The pharmacotherapy regimen for the intervention group was mebeverine hydrochloride 200 mg capsule once daily ( before breakfast ) and bismuth subcitrate 120 mg tablet twice daily (30 min before break

For the placebo group,mebeverine hydrochloride 200mg capsule once daily(before breakfast) and placebo of bismuth subcitrate(that did not have any effective material) 120 mg tablet twice daily(30 min b

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Diagnosis irritable bowel syndrome based on Rome 3 criteria; age>18 ; both sex. Exclusion criteria:age70 ; pregnancy; having a documented chronic heart or liver failure; surgery on the gastrointestinal tract except appendectomy; malabsorption diseases; hyperthyroidism; inflammatory bowel diseases; connective tissue diseases; severely progressive diseases, diabetes mellitus; use of antibiotic drugs within a month before the study; significant weight loss; fever; and bloody stools.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: 4 month wth monthly follow up. Method of measurement: IBS-qol questionare.;Bloating. Timepoint: 4 month wth monthly follow up. Method of measurement: questionare.;Abdominal pain. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.;Satisfaction of defication. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.;Ibs duration. Timepoint: 4 month wth monthly follow up. Method of measurement: questionare.;Age. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.;Sex. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.	—

Measure

Time frame

Quality of life. Timepoint: 4 month wth monthly follow up. Method of measurement: IBS-qol questionare.;Bloating. Timepoint: 4 month wth monthly follow up. Method of measurement: questionare.;Abdominal pain. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.;Satisfaction of defication. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.;Ibs duration. Timepoint: 4 month wth monthly follow up. Method of measurement: questionare.;Age. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.;Sex. Timepoint: 4 month wth monthly follow up. Method of measurement: Questionare.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Hamed Daghaghzadeh

Isfahan University of Medical Sciences

daghaghzadeh@med.mui.ac.ir+98 31 3669 3880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026